Table 4.

Mean (SD) and minimum-maximum values of Multiple Sclerosis Self-Efficacy Scale, Impact on Participation and Autonomy, and Partners In Health scores at baseline and at follow-up in the MSmonitor and control groups.

Empowerment aspects	MSmonitor (n=19)			Control (n=23)
	Baseline, mean (SD); minimum-maximum	4 months, mean (SD); minimum-maximum	P value	Baseline, mean (SD); minimum-maximum	4 months, mean (SD); minimum-maximum	P value
MSSESa control	59.8 (19.0), 20.0-87.8	63.4 (17.7), 32.2-94.4	.19	55.3 (19.5), 25.6-96.7	53.7 (20.8), 22.2-91.1	.40
MSSES function	72.4 (22.4), 28.9-100	73.5 (21.8), 30.0-100	.62	67.8 (24.3), 21.3-100	66.5 (23.5), 26.7-100	.17
IPAb limitations	2.8 (0.4), 1.7-3.6	2.7 (0.6), 1.6-3.7	.26	2.6 (0.7), 1.1-4.0	2.6 (0.6), 1.5-3.95	.28
IPA problems	0.71 (0.36), 0.00-1.71	0.79 (0.48), 0.00-1.86	.40	0.97 (0.35), 0.22-1.71	0.85 (0.35), 0.00-1.43	.25
PIHc coping	19.2 (3.3), 13.0-24.0	18.9 (4.8), 4.0-24.0	.73	18.6 (3.9), 8.0-24.0	18.9 (3.2), 12.0-24	.76
PIH symptoms	21.9 (1.2), 20.0-24.0	21.6 (2.3), 16.0-24.0	.52	20.8 (2.2), 16.0-24.0	20.9 (2.6), 13.0-24	.87
PIH adherence	15.1 (1.4), 11.0-16.0	14.9 (2.2), 8.0-16.0	.80	14.8 (1.4), 12.0-16.0	14.6 (2.3), 7.0-16	.34
PIH knowledge	28.7 (2.0), 25.0-32.0	27.8 (1.7), 24.0-30.0	.02	27.7 (3.4), 21.0-31.0	28.7 (2.2), 24.0-32	.24

^aMSSES: Multiple Sclerosis Self-Efficacy Scale.

^bIPA: Impact on Participation and Autonomy.

^cPIH: Partners In Health.